The ABCs Of Hepatitis

Emily BurkeDrug Targets, FDA, Mechanism of Action, Ribonucleic Acid (RNA), Small Molecule Drugs, The WEEKLY

Hepatitis Viruses Explained Curing disease is serious business. Lou Reed, the infamous leader of the rock band Velvet Underground, died in 2013 of complications from hepatitis C and liver disease. Death is the most profound fear for people living with hepatitis C, but with today’s treatments patients can beat this disease. Thank you Gilead’s (Foster City, CA) Harvoni or AbbVie’s (North … Read More

Cancer Immunotherapy Goes Viral

Emily BurkeBiologics, Cancer, Drug Approvals, Drug Targets, FDA, Mechanism of Action, The WEEKLY

Oncolytic Viruses Make Their Debut Does a virus engineered to harness the immune system to fight cancer sound like a clever idea? Amgen (Thousand Oaks, CA) certainly thinks so, because their talimogene laherparepvec (T-Vec) recently earned an FDA approval to fight inoperable melanoma recurrent after initial surgery. Oncolytic viruses—like T-Vec—have the attention of both industry media and mainstream news programs. This new class of therapy is an elegant “hack” of the immune … Read More

A Big Pain

Emily BurkeDrug Development, Drug Targets, Mechanism of Action, Small Molecule Drugs, The WEEKLY

The Science Behind Opioids President Obama’s recent plan to fight opioids highlights the dark side of a class of treatments serving a vital need. Opioid pain medications manage the severe short-term or chronic pain of millions of Americans. While these medications mitigate needless suffering, joining forces are the government, corporations, and medical community to battle against opioid abuse and addiction. Here at … Read More